Evicel Fibrin Sealant

Evicel Fibrin Sealant Uses, Dosage, Side Effects, Food Interaction and all others data.

Fibrinogen concentrate (human) is a hematological agent. It works by replacing a certain protein in the blood that helps with blood clotting. Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. It is a physiological substrate for three enzymes: plasmin, factor XIIIa and thrombin. It is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Fibrinogen replaces the missing, or low coagulation factor.

Trade Name Evicel Fibrin Sealant
Generic Fibrinogen human + thrombin human
Type Topical kit
Therapeutic Class
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Evicel Fibrin Sealant
Evicel Fibrin Sealant

Uses

Fibrinogen human is a hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Evicel Fibrin Sealant is also used to associated treatment for these conditions: Bleeding, Dura Mater Nick Cut or Tear, Surgical Bleeding, Acute bleeding episodes, Mild Bleeding, Moderate Bleeding, Tissue Adhesions, Maintenance of surgical hemostasis therapy

How Evicel Fibrin Sealant works

Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin. During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A and B (FPA and FPB, respectively). FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers. The resulting fibrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis. Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.

Volume of Distribution

Mean volume of distribution is 52.7 mL/kg.

Elimination Route

Cmax is 140 mg/dL

Half Life

78.7 hours

Clearance

0.59 mL/h/kg

Innovators Monograph

You find simplified version here Evicel Fibrin Sealant


*** Taking medicines without doctor's advice can cause long-term problems.
Share